Can this penny biotech stock make early-bird investors rich?
Canopy Growth Corporation, MyoKardia, and Blueprint Medicines are all outstanding healthcare picks this month.
Here's why Viking Therapeutics, Cambrex, and Sarepta Therapeutics are all solid biotech plays this month.
Amarin and Aphria could both be bought out soon.
AMN's shares are falling today after a weaker-than-expected fourth-quarter earnings report.
Pot shares might be wildly overvalued right now. Here's why.
This morning's move followed an upgrade by BTIG.
Dynavax's stock did a U-turn in January. Here's why.
Gilead's January rally turned out to be short-lived. Here's why.
AbbVie's fourth-quarter earnings release weighed heavily on its shares last month.
Agenus' stock crushed it last month. Here's why.
HEXO's shares ripped higher last month for two reasons.
A positive breast cancer trial readout sent this tiny biotech's shares rocketing higher.
These two white-hot pot stocks may have already crested.
Gilead's fourth-quarter numbers failed to hit the mark, but the company firmly believes that better days are directly ahead.
HEXO and OrganiGram Holdings could both turn out to be hidden gems.
A sudden change in leadership isn't sitting well with some of Nuvectra's shareholders.
With big money flowing in from the sidelines, these two pot companies are likely to be the first to be acquired.
Aphria has all the catalysts to become a top dog in the high-flying marijuana space.
Which of these two top pot stocks is the better buy right now?